Physician profile
Scott Luchsinger
NPI 1164467429
$11,876.44
in general payments reported to CMS, 2019-2025
43 companies · $2,384 in 2025
The $2,384 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,559 · 2020: $1,032 · 2021: $870 · 2022: $1,560 · 2023: $1,709 · 2024: $1,762 · 2025: $2,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,829 · Education: $27.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,828.51 |
| Education | $27.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,305.64 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,477.53 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Olympus Corporation of The Americas | $1,197.42 | 2019 | |
| Insmed, INC. | $927.39 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.65 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $569.16 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $373.45 | 2022-2025 | Tezspire, Tavneos |
| Electromed, INC. | $356.34 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $345.56 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $305.85 | 2021-2025 | Glassia |
| Genzyme Corporation | $245.16 | 2022-2025 | |
| United Therapeutics Corporation | $218.08 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Philips North America LLC | $164.48 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $157.54 | 2023-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $151.29 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $148.25 | 2021-2025 | Acthar |
| Mylan Specialty L.P. | $135.07 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $129.55 | 2023-2025 | Keytruda, Zerbaxa |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| La Jolla Pharmaceutical Company | $115.02 | 2024-2025 | Giapreza |
| Baxter Healthcare | $103.02 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $82.31 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $81.69 | 2019-2020 | |
| Edwards Lifesciences Corporation | $65.39 | 2021 | |
| Advanced Respiratory, INC | $55.12 | 2019-2021 | |
| Gilead Sciences, INC. | $55.02 | 2019-2022 | |
| Intuitive Surgical, INC. | $51.54 | 2022 | |
| Ani Pharmaceuticals, INC. | $44.46 | 2023-2024 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $44.46 | 2025 | Yupelri |
| Inogen, INC. | $35.54 | 2022 | |
| Phadia US INC. | $31.08 | 2019-2024 | Immunocap |
| Biogen, INC. | $23.64 | 2021 | |
| Csl Behring | $21.83 | 2021 | |
| Portola Pharmaceuticals, LLC | $19.57 | 2019 | |
| Pulmonx Corporation | $19.27 | 2022 | |
| Axsome Therapeutics, INC. | $18.29 | 2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $18.03 | 2025 | Lumryz |
| Vapotherm INC | $17.90 | 2022 | |
| Circassia INC. | $16.88 | 2019 | |
| Biomerieux INC | $15.67 | 2023 | |
| Verona Pharma, INC. | $14.41 | 2025 | Ohtuvayre |
| Ucb, INC. | $13.86 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Luchsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.